This is a pretty powerful statement from the editor of Journal of Alzheimer's Disease.
George Perry, Chairman of Synaptogenix's Scientific Advisory Board and Semmes Distinguished University Chair in Neurobiology at the University of Texas, recognized for his work on oxidative stress in AD, stated, "Restoration of vascular and oxidative balance now joins synaptic function as Bryostatin's benefits, offering the hope that Bryostatin will cure the key deficits of Alzheimer's disease and aging. These findings support Protein Kinase C epsilon (PKC e) as a master regulator of aging and Bryostatin as a candidate for prevention and disease reversal."
Market Data 
Markets 
AI
